Literature DB >> 1678607

Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes.

E Schön1, I Born, H U Demuth, J Faust, K Neubert, T Steinmetzer, A Barth, S Ansorge.   

Abstract

Dipeptidyl peptidase IV (DP IV) is a membrane peptidase playing a significant role in the process of activation and proliferation of human thymus-derived lymphocytes. This conclusion is drawn from (1) the induction of this enzyme on mitogen-activated T lymphocytes (cf. Schön, E. & Ansorge, S. (1990) Biol. Chem. Hoppe-Seyler 371, 699-705) and (2) the impairment of different functions of activated T cells in the presence of specific inhibitors and antibodies against DP IV (Schön, E. & al. (1987) Eur. J. Immunol 17, 1821-1826). This paper is aimed at testing new active site-specific peptide inhibitors for their efficiency as inhibitors of lymphocyte DP IV and DNA synthesis of mitogen-stimulated lymphocytes. These inhibitors comprise (i) diacylhydroxylamine derivatives of Xaa-Pro or Xaa-Ala peptides, (ii) different oligopeptides with N-terminal Xaa-Pro-sequences, and (iii) amino-acid amides of the pyrrolidide and the thiazolidide type. The thiazolidides of epsilon-(4-nitrobenzyloxycarbonyl)-L-lysine and of L-isoleucine as well as Ala-Pro-nitrobenzoylhydroxylamine are the most effective inhibitors in both test systems, yielding half-maximal inhibitory concentrations in the micromolar range. Cell viability was not impaired in this effective concentration range. Other inhibitors of DP IV are one to two orders of magnitude less efficient in the suppression of lymphocyte proliferation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1678607     DOI: 10.1515/bchm3.1991.372.1.305

Source DB:  PubMed          Journal:  Biol Chem Hoppe Seyler        ISSN: 0177-3593


  7 in total

1.  Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

Authors:  D Marguet; L Baggio; T Kobayashi; A M Bernard; M Pierres; P F Nielsen; U Ribel; T Watanabe; D J Drucker; N Wagtmann
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells.

Authors:  D Reinhold; U Bank; F Bühling; U Lendeckel; J Faust; K Neubert; S Ansorge
Journal:  Immunology       Date:  1997-07       Impact factor: 7.397

3.  Kinetic studies of novel inhibitors of endomorphin degrading enzymes.

Authors:  Renata Perlikowska; Jakub Fichna; Jean Claude do-Rego; Katarzyna Gach; Anna Janecka
Journal:  Med Chem Res       Date:  2011-05-20       Impact factor: 1.965

4.  Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules.

Authors:  K Falk; O Rötzschke; S Stevanović; G Jung; H G Rammensee
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

5.  Dipeptidyl-peptidase IV secreted by Aspergillus fumigatus, a fungus pathogenic to humans.

Authors:  A Beauvais; M Monod; J Wyniger; J P Debeaupuis; E Grouzmann; N Brakch; J Svab; A G Hovanessian; J P Latgé
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

6.  Serum protease activity in chronic kidney disease patients: The GANI_MED renal cohort.

Authors:  Carmen Wolke; Alexander Teumer; Karlhans Endlich; Nicole Endlich; Rainer Rettig; Sylvia Stracke; Beate Fiene; Simone Aymanns; Stephan B Felix; Anke Hannemann; Uwe Lendeckel
Journal:  Exp Biol Med (Maywood)       Date:  2016-12-30

Review 7.  Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.

Authors:  Carolyn F Deacon
Journal:  Nat Rev Endocrinol       Date:  2020-09-14       Impact factor: 43.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.